IVI in the Media

Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems

Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health


IVI Director General Jerome Kim Shares His Thoughts on the Current Challenges of Developing Vaccines for Global Health

2015-05-13 00:00
IVI Director General Jerome Kim shares his thoughts on the current challenges of developing vaccines for global health in Dong A Ilbo, one of Korea’s major newspapers.  He describes how organizations like IVI are filling the gaps in vaccine R&D for global health while at the same time contributing to Korea’s biotechnology sector.  The Korean-language article can be found here:
An English translation of the article is below.
[In My View]
Key players in vaccine development for developing countries
By Jerome Kim, Director-General, International Vaccine Institute
Eighteen years ago, Korea became host to the International Vaccine Institute (IVI), an international organization. IVI’s mission is to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
It can cost millions of dollars to develop and commercialize a vaccine, but IVI does not have the deep pool of financial resources to bring a vaccine to the market. IVI does not have the means to manufacture, distribute, and market a new product either.  The “business case” seems implausible. Yet there is an oral cholera vaccine now available for use in developing countries.  How did it come about? It was the result of a unique collaboration - IVI, Bill & Melinda Gates Foundation (BMGF), Korean government, and Korean and international vaccine companies.  In the field of vaccines, as in high tech industries, there is a space called the “valley of death” where most ideas for new vaccines end if there are high risks and costs involved. IVI serves as a bridge across the valley of death. IVI fills an important gap in vaccine development.
The development of the cholera vaccine was led by IVI with support from the Korean government and BMGF who has an interest in safe, effective, and affordable vaccines for global health.  IVI transferred the vaccine production technology to Korean and overseas companies and works with them to develop and manufacture . the vaccine.  Eubiologics, a Korean biotech company, recently received export approval for its cholera vaccine from the Korean Ministry of Food & Drug Safety. For every $1 of Korean government support to IVI, $2 of overseas funding are obtained by IVI to assist Korean vaccine companies to enter the global health vaccine market. IVI is also working with companies like SK Chemicals to commercialize a typhoid vaccine using the same partnership model.
The low-cost oral cholera vaccine has yielded results. Recently, there was a cholera outbreak in Malawi, following severe flooding.  More than 10,000 died from cholera outbreaks in Haiti in 2010 and South Sudan in 2013. In response to fears of a potentially massive cholera outbreak in Malawi, the government of Malawi, IVI, WHO, the government of Korea, and Kia Motors teamed up to vaccinate over 100,000 people using the cholera vaccine. IVI also joined forces with LG Electronics and conducted vaccinations in Ethiopia.  In Nepal, following the tragic earthquake, efforts are underway to deploy the vaccine.
IVI is only one of two non-profit organizations in the world that have successfully brought a vaccine for the public-sector market.  It isn’t often that ideas originating in a laboratory so clearly and dramatically impact a major public health emergency. It also shows the high value of government investment in biotechnology and vaccine research.
With support from Korea, organizations like IVI fill the gaps between a 21st century knowledge-based industry and the more basic needs of global health. This is an example of the creative economy that Korea is striving for.